Trelegy - Yahoo Search Results

- Theravance Biopharma (TBPH) to Sell Trelegy Royalty Interests
  Zacks via Yahoo Finance· 11 months ago
  Theravance Biopharma (TBPH) agrees to sell its Trelegy royalty interests to Royalty Pharma. The...
- A Life-long Asthma Patient Shares How She’s Learned to Manage Her Condition
  Parade via Yahoo News· 2 weeks ago
  Rashelle Stocker was diagnosed with asthma in third grade after having her first attack on the...
- Theravance Biopharma, Innoviva Gain On Selling TRELEGY ELLIPTA Royalty Interests
  Benzinga via Yahoo Finance· 11 months ago
  Theravance Biopharma, Inc. (NASDAQ: TBPH) has agreed to sell all of its units in Theravance...
- GSK's Q3 Earnings Beat, Ups 2022 Sales Outlook, Stock Up
  Zacks via Yahoo Finance· 7 months ago
  GSK plc GSK reported third-quarter 2022 adjusted earnings of $1.09 per American depositary share...
- Royalty Pharma plc (RPRX) Q2 2022 Earnings Call Transcript
  Motley Fool· 10 months ago
  Thank you for joining us to review Royalty Pharma's second quarter 2022 results. All forward-looking...
- GSK's Key Drugs to Drive Sales in a Sluggish Second Half
  Zacks via Yahoo Finance· 8 months ago
  GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Shingrix are driving sales, making up...
- GSK Gears Up to Report Q1 Earnings: What's in the Cards?
  Zacks via Yahoo Finance· 1 month ago
  GSK plc. GSK will report first-quarter 2023 results on Apr 26, before the opening bell. In the last...
- Why Is Glaxo (GSK) Up 6.7% Since Last Earnings Report?
  Zacks via Yahoo Finance· 6 months ago
  A month has gone by since the last earnings report for GSK (GSK). Shares have added about 6.7% in...
- Glaxo (GSK) Down 1.6% Since Last Earnings Report: Can It Rebound?
  Zacks via Yahoo Finance· 3 months ago
  It has been about a month since the last earnings report for GSK (GSK). Shares have lost about 1.6%...
- GSK's New Drugs and Pipeline Hold the Key to Growth in 2023
  Zacks via Yahoo Finance· 5 months ago
  GSK's specialty products like Dovato, Nucala, Trelegy Ellipta and Shingrix are likely to drive...